Exact Mass: 1130.4874

Exact Mass Matches: 1130.4874

Found 22 metabolites which its exact mass value is equals to given mass value 1130.4874, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Vapreotide

2-amino-N-[10-(4-aminobutyl)-4-{[1-carbamoyl-2-(1H-indol-2-yl)ethyl]carbamoyl}-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]-3-phenylpropanamide

C57H70N12O9S2 (1130.483)

Vapreotide is only found in individuals that have used or taken this drug. It is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (PMID: 7556407). Vapreotide is a neurokinin-1 (NK1) receptor antagonist, with an IC50 of 330 nM.

Pyrroindomycin B

Antibiotic 42D005beta

C60H79ClN4O15 (1130.523)

(2S,3S,4S,5R,6R)-6-[(11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-5-[(2R,3R,4S,5R,6S)-6-carboxy-3-[(2R,3R,4S,5S,6S)-6-carboxy-4,5-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid

NCGC00380232-01!(2S,3S,4S,5R,6R)-6-[(11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-5-[(2R,3R,4S,5R,6S)-6-carboxy-3-[(2R,3R,4S,5S,6S)-6-carboxy-4,5-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid

C54H82O25 (1130.5145)

Vapreotide

C57H70N12O9S2 (1130.483)

H - Systemic hormonal preparations, excl. sex hormones and insulins > H01 - Pituitary and hypothalamic hormones and analogues > H01C - Hypothalamic hormones > H01CB - Somatostatin and analogues C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C62799 - Somatostatin Receptor Agonist D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000970 - Antineoplastic Agents Vapreotide is a neurokinin-1 (NK1) receptor antagonist, with an IC50 of 330 nM.

Vapreotida

Vapreotide acetate salt

C57H70N12O9S2 (1130.483)

H - Systemic hormonal preparations, excl. sex hormones and insulins > H01 - Pituitary and hypothalamic hormones and analogues > H01C - Hypothalamic hormones > H01CB - Somatostatin and analogues D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000970 - Antineoplastic Agents Vapreotide is a neurokinin-1 (NK1) receptor antagonist, with an IC50 of 330 nM.

(21Z)-15-[4-[5-[5-amino-4-(7-chloro-3,4-dihydropyrrolo[2,3-b]indole-2-carbonyl)oxy-6-methyloxan-2-yl]oxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-methyloxan-2-yl]oxy-8-ethyl-9,21-dihydroxy-3,6,20-trimethyl-23,25-dioxo-24-azapentacyclo[20.2.1.01,6.011,20.014,19]pentacosa-4,12,21-triene-4-carboxylic acid

(21Z)-15-[4-[5-[5-amino-4-(7-chloro-3,4-dihydropyrrolo[2,3-b]indole-2-carbonyl)oxy-6-methyloxan-2-yl]oxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-methyloxan-2-yl]oxy-8-ethyl-9,21-dihydroxy-3,6,20-trimethyl-23,25-dioxo-24-azapentacyclo[20.2.1.01,6.011,20.014,19]pentacosa-4,12,21-triene-4-carboxylic acid

C60H79ClN4O15 (1130.523)

Dig-Cy5

C60H82N4O13S2 (1130.532)

(2S,3S,4S,5R,6R)-6-[(11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-5-[(2R,3R,4S,5R,6S)-6-carboxy-3-[(2R,3R,4S,5S,6S)-6-carboxy-4,5-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid

(2S,3S,4S,5R,6R)-6-[(11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-5-[(2R,3R,4S,5R,6S)-6-carboxy-3-[(2R,3R,4S,5S,6S)-6-carboxy-4,5-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid

C54H82O25 (1130.5145)

PIP3(38:2)

PIP3(16:0_22:2)

C47H90O22P4 (1130.4874)

Holothurin

C50H82O26S (1130.4815)

PIM2 33:9

C54H83O23P (1130.5062)

PIP3(3',4',5') 38:2

C47H90O22P4 (1130.4874)

PIP3 38:2

C47H90O22P4 (1130.4874)

15-{[4-({5-[(5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl)oxy]-4-hydroxy-4,6-dimethyloxan-2-yl}oxy)-5-methyloxan-2-yl]oxy}-8-ethyl-9,23,25-trihydroxy-3,6,20-trimethyl-21-oxo-24-azapentacyclo[20.2.1.0¹,⁶.0¹¹,²⁰.0¹⁴,¹⁹]pentacosa-4,12,22(25),23-tetraene-4-carboxylic acid

15-{[4-({5-[(5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl)oxy]-4-hydroxy-4,6-dimethyloxan-2-yl}oxy)-5-methyloxan-2-yl]oxy}-8-ethyl-9,23,25-trihydroxy-3,6,20-trimethyl-21-oxo-24-azapentacyclo[20.2.1.0¹,⁶.0¹¹,²⁰.0¹⁴,¹⁹]pentacosa-4,12,22(25),23-tetraene-4-carboxylic acid

C60H79ClN4O15 (1130.523)

(1r,3r,6r,8r,9s,11r,14r,15r,19r,20r)-15-{[(2s,5r,6r)-5-{[(2r,4s,5s,6r)-5-{[(2r,4s,5r,6s)-5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl]oxy}-4-hydroxy-4,6-dimethyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-8-ethyl-9,23,25-trihydroxy-3,6,20-trimethyl-21-oxo-24-azapentacyclo[20.2.1.0¹,⁶.0¹¹,²⁰.0¹⁴,¹⁹]pentacosa-4,12,22(25),23-tetraene-4-carboxylic acid

(1r,3r,6r,8r,9s,11r,14r,15r,19r,20r)-15-{[(2s,5r,6r)-5-{[(2r,4s,5s,6r)-5-{[(2r,4s,5r,6s)-5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl]oxy}-4-hydroxy-4,6-dimethyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-8-ethyl-9,23,25-trihydroxy-3,6,20-trimethyl-21-oxo-24-azapentacyclo[20.2.1.0¹,⁶.0¹¹,²⁰.0¹⁴,¹⁹]pentacosa-4,12,22(25),23-tetraene-4-carboxylic acid

C60H79ClN4O15 (1130.523)

11-{[(2s,5s,6s)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6r)-5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl]oxy}-4-hydroxy-4,6-dimethyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-18-ethyl-3,5,17-trihydroxy-6,20,23-trimethyl-25-oxo-2-azapentacyclo[18.3.1.1¹,⁴.0⁶,¹⁵.0⁷,¹²]pentacosa-2,4,13,21-tetraene-22-carboxylic acid

11-{[(2s,5s,6s)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6r)-5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl]oxy}-4-hydroxy-4,6-dimethyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-18-ethyl-3,5,17-trihydroxy-6,20,23-trimethyl-25-oxo-2-azapentacyclo[18.3.1.1¹,⁴.0⁶,¹⁵.0⁷,¹²]pentacosa-2,4,13,21-tetraene-22-carboxylic acid

C60H79ClN4O15 (1130.523)

n-[(3s,6r,9r,11s,15s,18s,20r,21r,24r,25r)-5,8,11,17,20,21,23,25-octahydroxy-3-[(1r)-1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-6-[(1r)-1-hydroxy-2-[4-hydroxy-3-(sulfooxy)phenyl]ethyl]-15-(hydroxymethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl]hexadecanimidic acid

n-[(3s,6r,9r,11s,15s,18s,20r,21r,24r,25r)-5,8,11,17,20,21,23,25-octahydroxy-3-[(1r)-1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-6-[(1r)-1-hydroxy-2-[4-hydroxy-3-(sulfooxy)phenyl]ethyl]-15-(hydroxymethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl]hexadecanimidic acid

C49H78N8O20S (1130.5053)

n-{5,8,11,17,20,21,23,25-octahydroxy-3-[1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-6-{1-hydroxy-2-[4-hydroxy-3-(sulfooxy)phenyl]ethyl}-15-(hydroxymethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl}hexadecanimidic acid

n-{5,8,11,17,20,21,23,25-octahydroxy-3-[1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-6-{1-hydroxy-2-[4-hydroxy-3-(sulfooxy)phenyl]ethyl}-15-(hydroxymethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl}hexadecanimidic acid

C49H78N8O20S (1130.5053)

11-{[5-({5-[(5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl)oxy]-4-hydroxy-4,6-dimethyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-18-ethyl-3,5,17-trihydroxy-6,20,23-trimethyl-25-oxo-2-azapentacyclo[18.3.1.1¹,⁴.0⁶,¹⁵.0⁷,¹²]pentacosa-2,4,13,21-tetraene-22-carboxylic acid

11-{[5-({5-[(5-amino-4-{5-chloro-1h,8h-pyrrolo[2,3-b]indole-2-carbonyloxy}-6-methyloxan-2-yl)oxy]-4-hydroxy-4,6-dimethyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-18-ethyl-3,5,17-trihydroxy-6,20,23-trimethyl-25-oxo-2-azapentacyclo[18.3.1.1¹,⁴.0⁶,¹⁵.0⁷,¹²]pentacosa-2,4,13,21-tetraene-22-carboxylic acid

C60H79ClN4O15 (1130.523)